Decision Makers
| Name (plus bio) |
Position |
| Brian A. Markison |
President and CEO |
| Carol A. Wrenn |
President, Animal Health |
| Eric J. Bruce |
President, Animal Health |
| Gregory D. Jordan |
President |
| Eric G. Carter |
Chief Science Officer |
| James Lattanzi |
CFO, Director |
| James W. Elrod |
Chief Legal Officer, Secretary |
| Joseph Squicciarino |
Chief Financial Officer |
| Steve Andrzejewski |
Chief Commercial Officer |
| Bradley Knoll |
Executive Vice President, Technical Operations |
| Dave Whitehead |
Executive Vice President, Sales |
| Dennis P. O'Brien |
Executive Vice President & President, Meridian Franchise |
| James E. Green |
Executive Vice President, Corp Affairs |
| Janet Tuffy |
Executive Vice President, Human Resources |
| Linda C. Wase |
Executive Vice President, Medical Affairs |
| Michael H. Davis |
Executive Vice President, Enterprise Technology |
| Richard G. Buecheler |
Executive Vice President, Quality |
| W. Clint Burrus |
Executive Vice President Managed Markets, Government and Trade |
| John Golubieski |
Vice President, Finance Planning & Analysis |
| Marsha Stanton |
Director of Advocacy and External Affairs |
| Ted G. Wood |
Lead Independent Director |
| Donna Polk |
Consultant |
| Edgar R Gonzalez |
Consultant |
| Frederick Brouillette Jr. |
Corp Compliance Officer |
| Murray Rosenthal |
Consultant |
| Raymond J Gibbons |
Consultant |
| Wendy P Painter |
Physician |
| Earnest W. Deavenport |
Director |
| Earnest W. Deavenport, JR. |
Director |
Board of Directors
Brian A. Markison currently serves as President, Chief Executive Officer and Chairman of the Board of Directors of King Pharmaceuticals, Inc. Prior to joining King Pharmaceuticals, Mr. Markison was the President of Oncology, Virology and Oncology Therapeutics Network Business at Bristol-Meyers Squibb. During his 22-year career at Bristol-Meyers Squibb, he distinguished himself in the areas of sales, marketing, international and domestic general management positions.
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
President and CEO |
Current |
| King Pharmaceuticals, Inc. |
Chairman of The Board of Directors |
Current |
| Immunomedics, Inc. |
Board of Directors |
Current |
| Immunomedics, Inc. |
President, Chief Executive Officer and Chairman of Board of Directors, King Pharmaceuticals, Inc |
Former |
| King Pharmaceuticals, Inc. |
Director |
Former |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
President, Animal Health |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
President, Animal Health |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
President |
Current |
| King Pharmaceuticals, Inc. |
Board of Directors |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Chief Science Officer |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
CFO, Director |
Current |
| King Pharmaceuticals, Inc. |
CFO & Director |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Chief Legal Officer, Secretary |
Current |
Mr. Squicciarino has served as the Chief Financial Officer of King Pharmaceuticals, Inc. since June 2005. Prior to joining King Pharmaceuticals, he served as Chief Financial Officer—North America for Revlon, Inc. from March 2005 until June 2009 and as Chief Financial Officer—International for Revlon International, Inc. from February 2003 until March 2005. He held the position of Group Controller Pharmaceuticals—Europe, Middle East, Africa with Johnson & Johnson from October 2001 until October 2002.
| Organization |
Position |
Status |
| Zep, Inc. |
Chief Financial Officer, King Pharmaceuticals, Inc. |
Current |
| King Pharmaceuticals, Inc. |
Chief Financial Officer |
Current |
| Zep, Inc. |
Chairman |
Current |
| Zep, Inc. |
Board of Directors |
Former |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Chief Commercial Officer |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Executive Vice President, Technical Operations |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Executive Vice President, Sales |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Executive Vice President & President, Meridian Franchise |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Executive Vice President, Corp Affairs |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Executive Vice President, Human Resources |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Executive Vice President, Medical Affairs |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Executive Vice President, Enterprise Technology |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Executive Vice President, Quality |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Executive Vice President Managed Markets, Government and Trade |
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Vice President, Finance Planning & Analysis |
Current |
Marsha Stanton is a registered nurse with a bachelor's degree in Health Services Administration and Education, a Master of Science in Health & Human Services, and a PhD in Health Services Administration and Education. She currently serves as the Director of Advocacy and External Affairs at King Pharmaceuticals. Her career has spanned clinical practice, program development, health professionals education, and advocacy development. She is nationally known for her work in the area of pain management, and has published and presented in this field. She has served in leadership roles with the American Society of Pain Management Nurses, Utah Pain Management Nurses, American Academy of Pain Management, and Pain Management Education Consultants. Prior to assuming her new position, she served as the Director of Medical Education at Purdue Pharma, L.P. and Director of Scientific Communication at Alpharma Pharmaceuticals. In these positions, she was responsible for professional education of nurses, nurse practitioners, physician assistants, physicians, pharmacists, and others at national, regional and international levels. In these roles, she served on the corporate advisory council for six professional associations. In 2006, she received the Distinguished Service Award from the American Society of Pain Management Nurses.
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Director of Advocacy and External Affairs |
Current |
| Nurse Practitioner Healthcare Foundation |
Board of Directors |
Current |
| The National Pain Foundation |
Board of Directors |
Current |
| Purdue Pharma L.P. |
Director of Medical Education |
Former |
| American Academy of Pain Management |
Board of Directors |
Former |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Lead Independent Director |
Current |
| Alpha Natural Resources, Inc. |
Director |
Current |
| Pharmaceutical Research and Manufacturers of America |
Director |
Current |
| KV Pharmaceutical Company |
CEO |
Former |
| KV Pharmaceutical Company |
President |
Former |
| GlaxoSmithKline Plc |
executive vice president, marketing and sales |
Former |
| SmithKline Beecham Corporation |
Executive Vice President, Marketing |
Former |
| King Pharmaceuticals, Inc. |
Chairman |
Former |
| POZEN, Inc. |
Board of Directors |
Former |
Dr. Polk has disclosed that she is a consultant for King Pharmaceuticals. She is also on the speakers' bureau for King Pharmaceuticals, Astellas Pharma, and Amgen.
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Consultant |
Current |
Dr. Gonzalez has disclosed that he is a consultant for King Pharmaceuticals. He is also on the speakers' bureaus for Astellas Pharma, Amgen, and King Pharmaceuticals.
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Consultant |
Current |
| Cmeohio |
|
Current |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Corp Compliance Officer |
Current |
| Organization |
Position |
Status |
| Quest Meded |
Medical Director, California Clinical Trials |
Current |
| Tetragenex Pharmaceuticals, Inc. |
Consultant |
Current |
| King Pharmaceuticals, Inc. |
Consultant |
Current |
Dr. Raymond Gibbons was born in New York City and grew up in northern New Jersey. He obtained a BSE in Aerospace and Mechanical Sciences from Princeton University, where he was valedictorian of his class. He completed a MSc in Mathematics at New College, Oxford University, where he studied on a Rhodes scholarship. After a year of graduate work in biomedical engineering at Johns Hopkins University, he completed his MD at Harvard Medical School, where he was a member of the Harvard-Massachusetts Institute of Technology Program in Health Sciences and Technology. He then completed a residency in internal medicine at Massachusetts General Hospital and a cardiology fellowship at Duke University Medical Center. In 1981, he joined the cardiology staff at the Mayo Clinic. Since that time, he has been Co-director of the Nuclear Cardiology Laboratory. In 1997, he was named the Arthur M. and Gladys D. Gray Professor of Medicine at Mayo Medical School. He has received numerous Mayo teaching awards in Internal Medicine and Cardiovascular Diseases. He is past Chair of the ACC-AHA Task Force on Practice Guidelines, past Chair of the ACC-AHA Writing Committee for Guidelines for Exercise Testing, Chair of the ACC Guidelines Applied in Practice Committee, and Chair of the Committee on Scientific Sessions Program of the AHA. He also serves as a member of the Board of Trustees of the American College of Cardiology and the Science Advisory and Coordinating Committee (the highest scientific policy group) of the AHA. Dr. Gibbons receives grant support from Medco Research (a division of King Pharmaceuticals), Wyeth-Ayerst, Medtronic, Radiant Medical, Alsius Corporation, TherOx, and Innercool Therapies. He is a consultant to CV Therapeutics, DOV Pharmaceuticals, King Pharmaceuticals, Medicure, Boehringer Ingelheim, and Hawaii Biotech. King Pharmaceuticals manufactures an angiotensin-converting enzyme (ACE) inhibitor. Because of this conflict of interest, he did not participate in the decision by the ACC/AHA Writing Committee for Guidelines for the Management of Patients with Chronic Stable Angina to recommend the use of ACE inhibitors.
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Consultant |
Current |
| Hawaii Biotech, Inc. |
Consultant |
Current |
| Boehringer Ingelheim Corporation |
Consultant |
Current |
| MedEncentive, LLC |
|
Current |
| Targegen, Inc. |
Board of Directors |
Current |
| Mayo Clinic |
Professor of Medicine |
Former |
| Harvard Medical School |
MD |
Former |
| New College |
Msc In Mathematics |
Former |
| Princeton University |
B.S.E. |
Former |
| Organization |
Position |
Status |
| Chimerix, Inc. |
Interim Chief Medical Officer |
Current |
| Drug Safety Alliance, Inc. |
Medical Director |
Current |
| King Pharmaceuticals, Inc. |
Physician |
Current |
| Triangle Pharmaceuticals, Inc. |
Physician |
Current |
| RTI |
|
Current |
| Research Triangle Institute |
|
Current |
| Trimeris, Inc. |
Medical Director |
Former |
| University of Miami |
M.D. |
Former |
| University of Miami School of Medicine |
M.D. |
Former |
| The University of North Carolina |
Master of Public Health In Epidemiology |
Former |
| University of North Carolina, Chapel Hill |
Mph In Epidemiology |
Former |
| Emory University |
M.S. Degree In Organic Chemistry |
Former |
| The University of North Carolina at Chapel Hill |
Mph In Epidemiology |
Former |
| Emory University |
B.S. Degree In Chemistry |
Former |
| Duke University |
Occupational Medicine |
Former |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Chair |
Current |
| Metacyte Business Lab LLC |
Board of Directors |
Current |
| King Pharmaceuticals, Inc. |
Board of Directors |
Former |
| Wake Forest |
Faculty |
Former |
| University of Louisville |
Faculty |
Former |
| Texas Tech University |
Chairman |
Former |
R. Charles Moyer is the Dean of the College of Business and Public Administration at the University of Louisville. Prior to joining the faculty at the University of Louisville, Dean Moyer was the Dean of the Babcock Graduate School of Management at Wake Forest University from 1996 until 2003. He also held the GMAC Insurance Chair of Finance. During his tenure as Dean, the Babcock School was named among the top business schools in the world in every major ranking of MBA programs. Prior to joining the faculty at Wake Forest in 1988, he was Finance Department Chairman at Texas Tech University. He has also taught at the University of Houston, Lehigh University, and the University of New Mexico. Dean Moyer is a member of the Board of Directors of King Pharmaceuticals, Inc. and Amarr Garage Doors, Inc.
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Board of Directors |
Current |
| Metacyte Business Lab LLC |
Board of Directors |
Current |
| Babcock Graduate School of Management at Wake Forest University |
Dean |
Former |
| The University of Houston |
|
Former |
| Texas Tech University |
Finance Department Chairman |
Former |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Board of Directors |
Current |
Mr. Deavenport has served as a Director since October 2007. He is the retired Chairman and Chief Executive Officer of Eastman Chemical Company, and served in those positions from 1994 to 2002. Mr. Deavenport served as a director of Acuity Brands from June 2002 until October 2007. Mr. Deavenport serves as Lead Director, is Chairman of our Compensation Committee and is a member of our Nominating and Corporate Governance Committee. He is a director of King Pharmaceuticals, Inc. and Regions Financial Corporation.
| Organization |
Position |
Status |
| Eastman Chemical Company |
Chief Executive Officer |
Current |
| Zep, Inc. |
Board of Directors |
Current |
| Zep, Inc. |
Chair |
Current |
| Eastman Chemical Company |
Chairman |
Current |
| Regions Financial Corporation |
Board of Directors |
Current |
| King Pharmaceuticals, Inc. |
Director |
Current |
| National Association of Manufacturers |
Chairman |
Former |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Director |
Current |
| Acuity Brands, Inc. |
Board of Directors |
Current |
| Regions Insurance Group, Inc. |
Board of Directors |
Current |
| R&M Properties |
Board of Directors |
Current |
| Zep, Inc. |
Director |
Current |
| Eastman Chemical Company |
Chief Executive Officer |
Former |
| National Association of Manufacturers |
Chairman |
Former |
| Eastman Chemical Company |
Chairman |
Former |
| Regions Financial Corporation |
Director |
Former |
| Organization |
Position |
Status |
| King Pharmaceuticals, Inc. |
Board of Directors |
Current |
| Organization |
Position |
Status |
| McLaren Health Care Corporation |
Chief Executive Officer |
Current |
| McLaren Health Care Corporation |
President |
Current |
| InteliStaf Healthcare, Inc. |
Board of Directors |
Current |
| King Pharmaceuticals, Inc. |
Board of Directors |
Current |
| The Regents |
Chairman |
Former |
Executive News
-
King's Crossroads
Business Tennessee Magazine - 6/18/09 - View Story
-
King Pharmaceuticals Taps John Howarth as VP of Investor Relations
TradingMarkets - 6/05/09 - View Story
-
King Pharmaceuticals Appoints John J. Howarth Vice President Investor Relations
Forbes.com - 6/01/09 - View Story
-
King Pharmaceuticals Appoints John J. Howarth Vice President
Business Wire via MSN Money - 6/01/09 - View Story
-
King Pharmaceuticals Appoints John J. Howarth Vice President Investor Relations
Yahoo! Canada - 6/01/09 - View Story